<p>Incyte Corporation announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of event-free survival (EFS), with no new safety signals observed. Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for the combination therapy in the first half of 2026. The results have been announced, and further regulatory submissions are planned. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105730167) on January 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Incyte Reports Positive Phase 3 Results for Tafasitamab Combo in First-Line DLBCL